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Since the discovery of HAM/TSP, little progress has been
made on developing treatments. As HAM/TSP usually
progress slowly, it can take a long time to evaluate disease
activity and decide on a course of treatment. Therefore,
there is a dire need for biomarkers capable of predicting
the rate of disease progression and “surrogate end-points”
that enable new treatments to be assessed more rapidly
and with greater accuracy in clinical trials. However, in
order to validate surrogate end-points, it is necessary to
conduct large-scale, randomized clinical trials – a very dif-
ficult feat for such a rare disease. Here we present a recent
study on candidate prognostic biomarkers for HAM/TSP
and discuss future research directions.
Published: 7 January 2014
doi:10.1186/1742-4690-11-S1-O28
Cite this article as: Yamano: Wish list: which biomarker studies in HAM/
TSP should be funded by the God of all trial funds? Retrovirology 2014
11(Suppl 1):O28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitDepartment of Rare Diseases Research, Institute of Medical Science, St.
Marianna University School of Medicine, Kawasaki, Japan
Yamano Retrovirology 2014, 11(Suppl 1):O28
http://www.retrovirology.com/content/11/S1/O28
© 2014 Yamano; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
